/

2137.HK

BRII-BClosed

0.8350−0.01 −1.18%HKD

HKSE · as of Oct 14, 04:08 ET · 15m delay

Open

0.8400

Prev close

0.8450

Day range

0.82500.8550

52-week range

0.81501.99

Volume

359.25K0.59×

Mkt cap

603.03M

P/E ttm

—

Fwd P/E

-1.64

EPS ttm

-0.2800

Div yield

0.00%

Earnings

—

From 52w high

−58.04%

Price Chart

Yahoo Finance · delayed

2137.HKOct 14, 2026O 0.8400H 0.8550L 0.8250C 0.8350−0.0100 (−1.18%)Vol 359.25K

SMA 500.9174
SMA 2001.2122

1Y change −57.61% since Oct 13, 2025 close529 bars loadedTimes in Asia/Hong_KongDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

2137.HK BRII-B · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −4.02%
1 month: −5.11%
3 months: −20.48%
6 months: −41.20%
Year to date: −40.36%
1 year: −56.05%

Valuation & ownership

Market cap: 603.03M
Enterprise value: −1.21B
P/E (ttm): —
Forward P/E: -1.64
PEG ratio: —
Price / book: 0.23
Price / sales (ttm): 17.30
EV / EBITDA: 4.61
EPS (ttm): -0.2800
EPS (forward): -0.5083
Beta (5y monthly): 1.25
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 722.19M
Float: 594.84M
Short % of float: —
Short ratio (days): —
Held by insiders: 5.07%
Held by institutions: 12.72%
Avg volume (3m): 612.50K
50-day average: 0.9194
200-day average: 1.22
52-week change: −56.05%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 35.7
vs 50-day SMA: −8.98%
vs 200-day SMA: −31.12%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.50%
Realised vol (20d, ann.): 22.8%
From 52-week high: −58.04%
From 52-week low: +2.45%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 34.85M
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 100.00%
Operating margin: -755.10%
Profit margin: 0.00%

DES

About BRII-B

Yahoo Finance profile

Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in c for the treatment of HIV. It also develops Soralimixinfor the treatment of multi-drug resistant or extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with treatment-refractory mycobacterium avium complex (MAC) lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.

Sector: Healthcare
Industry: Biotechnology
Employees: 80
Headquarters: Beijing, China
Website: briibio.com
Officers: Dr. Zhi Hong Ph.D. Co-founder, Executive Chairman of the Board & CEO
Dr. Ankang Li C.F.A., J.D., Ph.D. COO, Joint Secretary & Executive Director
Dr. Eleanor de Groot Ph.D. Chief Technology Officer

SEAS

Seasonality · 2137.HK

2021–2026 · monthly returns

Strongest month Nov +28.63%Weakest month Mar −17.18%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	7.9	3.3	-12.8	-0.7	-14.8	-16.5	-2.1	-2.1	-6.0	-3.5			−40.4%
2025	12.0	71.4	27.6	-20.4	-5.6	-8.2	18.9	-7.5	7.5	-9.0	-4.4	-19.5	+40.0%
2024	-28.9	2.5	-45.2	37.4	-6.4	-13.7	1.0	-2.9	28.3	-18.9	-5.8	3.1	−56.1%
2023	37.3	-41.3	-27.3	-0.7	-12.8	-16.0	10.2	-17.6	-11.9	-4.0	15.8	-18.3	−69.1%
2022	-49.7	-12.4	-23.9	-23.4	-0.9	0.5	8.7	-14.2	-32.8	5.5	54.2	-14.5	−77.7%
2021								44.4	8.2	-37.5	83.4	-26.1	+32.2%

INSD

Insider Activity · 2137.HK

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 23, 2026	Li (Ankang)Director (Executive)	Sale at price 0.11 per share.	43.5K	$4.71K
Sep 20, 2026	Hong (Zhi)Chief Executive Officer	—	60.8K	—
Sep 20, 2026	Li (Ankang)Director (Executive)	—	285.4K	—
Aug 26, 2026	Li (Ankang)Director (Executive)	Sale at price 0.12 per share.	1.5K	$182
Aug 25, 2026	Hong (Zhi)Chief Executive Officer	—	65K	—
Aug 25, 2026	Li (Ankang)Director (Executive)	—	36.1K	—
Oct 30, 2025	Li (Ankang)Director (Executive)	—	20.5K	—
Oct 29, 2025	Hong (Zhi)Chief Executive Officer	—	124.8K	—
Oct 26, 2025	Li (Ankang)Director (Executive)	—	57.8K	—
Sep 25, 2025	Li (Ankang)Director (Executive)	Sale at price 0.24 per share.	72.5K	$17.42K
Sep 23, 2025	Hong (Zhi)Chief Executive Officer	—	60.6K	—
Sep 21, 2025	Li (Ankang)Director (Executive)	—	325.9K	—
Sep 17, 2025	Hong (Zhi)Chief Executive Officer	—	32.4K	—
Sep 16, 2025	Li (Ankang)Director (Executive)	—	20.3K	—
Sep 9, 2025	Yang TaiyinIndependent Non-Executive Director	—	109K	—
Aug 27, 2025	Li (Ankang)Director (Executive)	Sale at price 0.24 per share.	2.5K	$603
Aug 25, 2025	Li (Ankang)Director (Executive)	—	36.1K	—
Aug 24, 2025	Hong (Zhi)Chief Executive Officer	—	64.8K	—
Jan 5, 2025	Hong (Zhi)Chief Executive Officer	Acquisition at price 0.13 per share.	34.3K	$4.41K
Jan 2, 2025	Hong (Zhi)Chief Executive Officer	Acquisition at price 0.13 per share.	73K	$9.19K

2137.HK

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

2137.HK

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About BRII-B

Seasonality · 2137.HK

Insider Activity · 2137.HK

Congress Trades · 2137.HK

Investors Holding 2137.HK

Investors Holding 2137.HK

Congress Trades · 2137.HK

Insider Activity · 2137.HK

Seasonality · 2137.HK

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About BRII-B

Earnings & Dividends

News